Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was -0.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:
- Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY
Management is scheduled to participate in a fireside chat on Wednesday, September 13th at 7:50 a.m. Pacific Time / 10:50 a.m. Eastern Time.
- Gilmartin Group Emerging Growth Company Showcase, Virtual
Management is scheduled to present on Thursday, September 21st at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time.
Interested parties may access live and archived webcasts of the presentations on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio